Stop taking this medicine immediately if you notice the appearance of a skin rash or any lesions inside the mouth or on the genitals, or any other sign of allergy.
During treatment with nonsteroidal anti-inflammatory drugs, cases of fluid retention and swelling (especially in ankles and legs), increased blood pressure, and heart failure have been reported.
Medicines like Enantyum may be associated with a small increased risk of suffering a heart attack ("myocardial infarction") or a stroke ("cerebral infarction").
In patients with autoimmune disorders affecting connective tissue (systemic lupus erythematosus or mixed connective tissue disease), anti-inflammatory drugs may rarely cause fever, headache, and neck stiffness.
The most commonly observed side effects are of a gastrointestinal nature. They may cause peptic ulcers, perforation, or gastrointestinal bleeding, sometimes fatal, especially in elderly patients.
After administration, nausea, vomiting, diarrhea, flatulence, constipation, dyspepsia, abdominal pain, melena, hematemesis, ulcerative stomatitis, worsening of colitis, and Crohn's disease have been reported. Less frequently, gastric wall inflammation (gastritis) has been observed.
Like other NSAIDs, hematological reactions (purpura, aplastic and hemolytic anemia, and more rarely agranulocytosis and medullary hypoplasia) may appear.
Reporting of side effects
If you experience any type of side effect, consult your doctor, pharmacist, or nurse, even if it is a possible side effect that does not appear in this prospectus. You can also report them directly through the Spanish System for the Pharmacovigilance of Medicines for Human Use:www.notificaRAM.es.
By reporting side effects, you can contribute to providing more information on the safety of this medicine.
Keep this medication out of the sight and reach of children.
Do not usethis medicationafter the expiration date that appears on the packaging and on the blister pack after CAD. The expiration date is the last day of the month indicated.
Do not store at a temperature above 30 °C. Store the blister packs in the original packaging to protect them from light.
Medicines should not be disposed of through drains or in the trash. Dispose of the packaging and medications you no longer need at the SIGRE collection pointat the pharmacy. If in doubt, ask your pharmacist how to dispose of the packaging and medications you no longer need. By doing so, you will help protect the environment.
Composition of Enantyum
- The active ingredient is dexketoprofen (as dexketoprofen trometamol). Each capsule contains 25 mg of dexketoprofen.
- The other components are:
Content of the capsule: microcrystalline cellulose, cornstarch, glyceryl distearate, and carboxymethylstarch sodium (Type A) (potato starch).
Composition of the capsule (body and cap): gelatin, titanium dioxide (E171), water, quinoline yellow (E104), and patent blue V (E131).
Appearance of Enantyum and content of the packaging
Durable gelatin capsules of green color, containing a white granulate.
The capsules are packaged in Aclar/PVC/Aluminum blisters.
It is presented in packaging that contains 20 and 500 hard capsules.
Holder of the marketing authorization and responsible for manufacturing
Laboratorios Menarini, S.A.
Alfons XII, 587
08918 Badalona (Barcelona) Spain
Date of the last review of this leaflet: April 2023.
Other sources of information
The detailed and updated information on this medication is available on the website of the Spanish Agency for Medicines and Medical Devices (AEMPS) http://www.aemps.gob.es/.
Have questions about this medication or your symptoms? Connect with a licensed doctor for guidance and personalized care.